ACADIA Pharmaceuticals, Inc. To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2006 On February 14, 2006
SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. , a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the BIO CEO & Investor Conference 2006 on Tuesday, February 14, 2006, at 12:00 p.m. Eastern Time at the Waldorf=Astoria Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through February 28, 2006.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for CNS disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, neuropathic pain, and glaucoma. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
Contacts: ACADIA Pharmaceuticals Inc. Lisa Barthelemy, Director, Investor Relations Thomas H. Aasen, Vice President and Chief Financial Officer (858) 558-2871ACADIA Pharmaceuticals Inc.
CONTACT: Lisa Barthelemy, Director, Investor Relations, or Thomas H.Aasen, Vice President and Chief Financial Officer, both of ACADIAPharmaceuticals Inc., +1-858-558-2871
Web site: http://www.acadia-pharm.com/